<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330459</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU FAMPLAN 6734</org_study_id>
    <nct_id>NCT01330459</nct_id>
  </id_info>
  <brief_title>Hydrocodone For Pain Control in First Trimester Surgical Abortion</brief_title>
  <official_title>An Evaluation of Hydrocodone/Acetaminophen for Pain Control in First Trimester Surgical Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Micks</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Planned Parenthood Federation of America</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preoperatively administered
      hydrocodone/acetaminophen (HC/APAP) reduces pain during a first trimester surgical abortion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to conduct a double-blinded randomized placebo-controlled trial of 120
      women undergoing elective first trimester surgical abortion. These women will be premedicated
      with either two tabs of 5/350 hydrocodone/acetaminophen or 2 tabs of a placebo. All subjects
      will receive ibuprofen and lorazepam preoperatively and a PCB. This study will examine the
      incremental benefit of HC/APAP over this standard medication regimen. Randomization will be
      stratified into two groups. Subjects less than 8 weeks gestation will comprise the early
      gestational age group. Subjects between 8 weeks 0 days and 10 weeks 6 days will comprise the
      late gestational age group. The investigators will be assessing patient perception of pain,
      nausea, satisfaction, and anxiety at multiple points during the clinic visit using 100-mm
      visual analogue scales (VAS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Perception of Pain</measure>
    <time_frame>At time of uterine aspiration (baseline)</time_frame>
    <description>To determine whether HC/APAP, given in addition to a standard regimen of ibuprofen, lorazepam, and PCB, affects patient pain perception at the time of uterine aspiration, as measured by distance (mm) from the left of the 100 mm visual analog scale (VAS). The number 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Pain During Cervical Dilation</measure>
    <time_frame>During procedure (approximately 45-90 min after hydrocodone/acetaminophen or placebo, and within 5 minutes of procedure starting)</time_frame>
    <description>Distance (mm) from the left of the 100 mm VAS scale (VAS anchors: 0 = none, 100 mm = worst imaginable) recorded after cervical dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Pain Control</measure>
    <time_frame>30 minutes after completion of the procedure (which started 45-90 minutes after study drug administration)</time_frame>
    <description>Distance (mm) from the left of the 100 mm VAS (VAS anchors: 0 = unsatisfied, 100 mm = very satisfied) recorded 30 minutes after completion of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea</measure>
    <time_frame>30 minutes after completion of the procedure (which started 45-90 minutes after study drug administration)</time_frame>
    <description>To assess whether HC/APAP is associated with nausea, measured on the 100 mm VAS, recorded 30 minutes postoperatively. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Additional Intraoperative and/or Postoperative Pain Medication</measure>
    <time_frame>30 minutes after completion of the procedure (which started 45-90 minutes after study drug administration)</time_frame>
    <description>To assess need for additional intraoperative and/or postoperative pain medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Hydrocodone/acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.
Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.
Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone/acetaminophen</intervention_name>
    <description>Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.</description>
    <arm_group_label>Hydrocodone/acetaminophen</arm_group_label>
    <other_name>Vicodin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>800 mg oral ibuprofen</description>
    <arm_group_label>Hydrocodone/acetaminophen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>2 mg oral lorazepam</description>
    <arm_group_label>Hydrocodone/acetaminophen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>20 ml 1% buffered lidocaine, injected</description>
    <arm_group_label>Hydrocodone/acetaminophen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Voluntarily requesting surgical pregnancy termination

          -  Pregnancy with intrauterine gestational sac up to 10 weeks 6 days gestation, dated by
             ultrasound

          -  Eligible for suction curettage

          -  English or Spanish speaking

          -  Good general health

          -  Able and willing to give informed consent and agree to terms of the study

        Exclusion Criteria:

          -  Gestational ages 11 weeks or more

          -  Incomplete abortion

          -  Premedication with misoprostol

          -  Use of any opioid medication within the past 7 days

          -  Use of heroin within the past 7 days

          -  Requested opioids or IV sedation prior to start of the procedure

          -  Patients who refuse ibuprofen or lorazepam

          -  Contraindications or allergies to HC/APAP, lidocaine, ibuprofen, or lorazepam

          -  Significant medical problem necessitating inpatient procedure

          -  Adnexal mass or tenderness on pelvic exam consistent with pelvic inflammatory disease

          -  Known hepatic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Micks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood CW</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/9991CD/DUPLICATIONSHIELDSYNC/331953/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2165/ContentSetId/31/SearchOption/BeginWith#secN1069D</url>
    <description>Micromedex (2010). Hydrocodone bitartrate/acetaminophen</description>
  </link>
  <reference>
    <citation>Allen RH, Kumar D, Fitzmaurice G, Lifford KL, Goldberg AB. Pain management of first-trimester surgical abortion: effects of selection of local anesthesia with and without lorazepam or intravenous sedation. Contraception. 2006 Nov;74(5):407-13. Epub 2006 Aug 2.</citation>
    <PMID>17046383</PMID>
  </reference>
  <reference>
    <citation>Bélanger E, Melzack R, Lauzon P. Pain of first-trimester abortion: a study of psychosocial and medical predictors. Pain. 1989 Mar;36(3):339-50.</citation>
    <PMID>2710563</PMID>
  </reference>
  <reference>
    <citation>Bone ME, Dowson S, Smith G. A comparison of nalbuphine with fentanyl for postoperative pain relief following termination of pregnancy under day care anaesthesia. Anaesthesia. 1988 Mar;43(3):194-7.</citation>
    <PMID>3364636</PMID>
  </reference>
  <reference>
    <citation>Dahl V, Fjellanger F, Raeder JC. No effect of preoperative paracetamol and codeine suppositories for pain after termination of pregnancies in general anaesthesia. Eur J Pain. 2000;4(2):211-5.</citation>
    <PMID>10957701</PMID>
  </reference>
  <reference>
    <citation>Edelman A, Nichols MD, Jensen J. Comparison of pain and time of procedures with two first-trimester abortion techniques performed by residents and faculty. Am J Obstet Gynecol. 2001 Jun;184(7):1564-7.</citation>
    <PMID>11408881</PMID>
  </reference>
  <reference>
    <citation>Edelman A, Nichols MD, Leclair C, Astley S, Shy K, Jensen JT. Intrauterine lidocaine infusion for pain management in first-trimester abortions. Obstet Gynecol. 2004 Jun;103(6):1267-72.</citation>
    <PMID>15172863</PMID>
  </reference>
  <reference>
    <citation>Edelman A, Nichols MD, Leclair C, Jensen JT. Four percent intrauterine lidocaine infusion for pain management in first-trimester abortions. Obstet Gynecol. 2006 Feb;107(2 Pt 1):269-75.</citation>
    <PMID>16449111</PMID>
  </reference>
  <reference>
    <citation>Heath PJ, Ogg TW. Prophylactic analgesia for daycase termination of pregnancy. A double-blind study with controlled release dihydrocodeine. Anaesthesia. 1989 Dec;44(12):991-4.</citation>
    <PMID>2619027</PMID>
  </reference>
  <reference>
    <citation>Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003 Sep;4(7):407-14.</citation>
    <PMID>14622683</PMID>
  </reference>
  <reference>
    <citation>Kan AS, Ng EH, Ho PC. The role and comparison of two techniques of paracervical block for pain relief during suction evacuation for first-trimester pregnancy termination. Contraception. 2004 Aug;70(2):159-63.</citation>
    <PMID>15288222</PMID>
  </reference>
  <reference>
    <citation>Nichols, M. D., Halvorson-Boyd, G., Goldstein, R., Gevirtz, C., &amp; Healow, D. (2009). Pain management. In M. Paul, E. S. Lichtenberg, L. Borgatta, D. A. Grimes &amp; P. G. Stubblefield (Eds.), Management of unintended and abnormal pregnancy. (pp. 90-110): Wiley-Blackwell.</citation>
  </reference>
  <reference>
    <citation>O'Connell K, Jones HE, Simon M, Saporta V, Paul M, Lichtenberg ES; National Abortion Federation Members. First-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2009 May;79(5):385-92. doi: 10.1016/j.contraception.2008.11.005. Epub 2008 Dec 11.</citation>
    <PMID>19341852</PMID>
  </reference>
  <reference>
    <citation>Renner RM, Jensen JT, Nichols MD, Edelman A. Pain control in first trimester surgical abortion. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006712. doi: 10.1002/14651858.CD006712.pub2. Review.</citation>
    <PMID>19370649</PMID>
  </reference>
  <reference>
    <citation>Romero I, Turok D, Gilliam M. A randomized trial of tramadol versus ibuprofen as an adjunct to pain control during vacuum aspiration abortion. Contraception. 2008 Jan;77(1):56-9. Epub 2007 Nov 26.</citation>
    <PMID>18082668</PMID>
  </reference>
  <reference>
    <citation>Rowbotham MC. What is a &quot;clinically meaningful&quot; reduction in pain? Pain. 2001 Nov;94(2):131-2. Review.</citation>
    <PMID>11690725</PMID>
  </reference>
  <reference>
    <citation>Singh RH, Ghanem KG, Burke AE, Nichols MD, Rogers K, Blumenthal PD. Predictors and perception of pain in women undergoing first trimester surgical abortion. Contraception. 2008 Aug;78(2):155-61. doi: 10.1016/j.contraception.2008.03.011. Epub 2008 May 27.</citation>
    <PMID>18672118</PMID>
  </reference>
  <reference>
    <citation>Suprapto K, Reed S. Naproxen sodium for pain relief in first-trimester abortion. Am J Obstet Gynecol. 1984 Dec 15;150(8):1000-1.</citation>
    <PMID>6507524</PMID>
  </reference>
  <reference>
    <citation>Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996 Apr;27(4):485-9.</citation>
    <PMID>8604867</PMID>
  </reference>
  <reference>
    <citation>Uppington, J. (2006). Opioids. In J. Ballantyne (Ed.), Massachusetts General Hospital Handbook of Pain Management (pp. 106-126). Philadelphia: Lippincott Williams &amp; Wilkins.</citation>
  </reference>
  <reference>
    <citation>WHO (2003). Safe abortion:Technical and policy guidance for health systems</citation>
  </reference>
  <reference>
    <citation>Wiebe E, Podhradsky L, Dijak V. The effect of lorazepam on pain and anxiety in abortion. Contraception. 2003 Mar;67(3):219-21.</citation>
    <PMID>12618257</PMID>
  </reference>
  <reference>
    <citation>Wiebe ER, Rawling M. Pain control in abortion. Int J Gynaecol Obstet. 1995 Jul;50(1):41-6.</citation>
    <PMID>7556858</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2011</study_first_posted>
  <results_first_submitted>February 28, 2019</results_first_submitted>
  <results_first_submitted_qc>April 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Elizabeth Micks</investigator_full_name>
    <investigator_title>Fellow in Family Planning</investigator_title>
  </responsible_party>
  <keyword>Pain during first trimester surgical abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects in this study are women 18 years or older, recruited from OHSU and PPCW who present for an elective termination of pregnancy up to 10 weeks 6 days gestation</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hydrocodone/Acetaminophen</title>
          <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydrocodone/Acetaminophen</title>
          <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="6.3"/>
                    <measurement group_id="B2" value="24.7" spread="4.5"/>
                    <measurement group_id="B3" value="25.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Perception of Pain</title>
        <description>To determine whether HC/APAP, given in addition to a standard regimen of ibuprofen, lorazepam, and PCB, affects patient pain perception at the time of uterine aspiration, as measured by distance (mm) from the left of the 100 mm visual analog scale (VAS). The number 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
        <time_frame>At time of uterine aspiration (baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocodone/Acetaminophen</title>
            <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Pain</title>
          <description>To determine whether HC/APAP, given in addition to a standard regimen of ibuprofen, lorazepam, and PCB, affects patient pain perception at the time of uterine aspiration, as measured by distance (mm) from the left of the 100 mm visual analog scale (VAS). The number 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" spread="25.4"/>
                    <measurement group_id="O2" value="63.1" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Pain During Cervical Dilation</title>
        <description>Distance (mm) from the left of the 100 mm VAS scale (VAS anchors: 0 = none, 100 mm = worst imaginable) recorded after cervical dilation</description>
        <time_frame>During procedure (approximately 45-90 min after hydrocodone/acetaminophen or placebo, and within 5 minutes of procedure starting)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocodone/Acetaminophen</title>
            <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Pain During Cervical Dilation</title>
          <description>Distance (mm) from the left of the 100 mm VAS scale (VAS anchors: 0 = none, 100 mm = worst imaginable) recorded after cervical dilation</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.2" spread="26.8"/>
                    <measurement group_id="O2" value="43.9" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Pain Control</title>
        <description>Distance (mm) from the left of the 100 mm VAS (VAS anchors: 0 = unsatisfied, 100 mm = very satisfied) recorded 30 minutes after completion of the procedure.</description>
        <time_frame>30 minutes after completion of the procedure (which started 45-90 minutes after study drug administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocodone/Acetaminophen</title>
            <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Pain Control</title>
          <description>Distance (mm) from the left of the 100 mm VAS (VAS anchors: 0 = unsatisfied, 100 mm = very satisfied) recorded 30 minutes after completion of the procedure.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="24.7"/>
                    <measurement group_id="O2" value="67.3" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Nausea</title>
        <description>To assess whether HC/APAP is associated with nausea, measured on the 100 mm VAS, recorded 30 minutes postoperatively. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
        <time_frame>30 minutes after completion of the procedure (which started 45-90 minutes after study drug administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocodone/Acetaminophen</title>
            <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea</title>
          <description>To assess whether HC/APAP is associated with nausea, measured on the 100 mm VAS, recorded 30 minutes postoperatively. VAS anchors: 0 indicates no pain, and 100 indicates worst pain imaginable.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="27.0"/>
                    <measurement group_id="O2" value="11.4" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Additional Intraoperative and/or Postoperative Pain Medication</title>
        <description>To assess need for additional intraoperative and/or postoperative pain medication</description>
        <time_frame>30 minutes after completion of the procedure (which started 45-90 minutes after study drug administration)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydrocodone/Acetaminophen</title>
            <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.
Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure.
Hydrocodone/acetaminophen: Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
Ibuprofen: 800 mg oral ibuprofen
Lorazepam: 2 mg oral lorazepam
Lidocaine: 20 ml 1% buffered lidocaine, injected</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.
Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure.
Placebo: Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
Ibuprofen: 800 mg oral ibuprofen
Lorazepam: 2 mg oral lorazepam
Lidocaine: 20 ml 1% buffered lidocaine, injected</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Additional Intraoperative and/or Postoperative Pain Medication</title>
          <description>To assess need for additional intraoperative and/or postoperative pain medication</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hydrocodone/Acetaminophen</title>
          <description>Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subject will receive placebo 45-90 minutes prior to abortion procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hematometra requiring reaspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Edelman, MD, Assistant Professor</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>(503) 494-3666</phone>
      <email>edelmana@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

